VisionAware

A recent study, published in Graefe’s Archive for Clinical and Experimental Ophthalmology, has attempted to “identify factors and problems influencing treatment adherence in patients undergoing anti-VEGF therapy for neovascular age-related macular degeneration under real-life conditions.” Graefe’s Archive is an international journal that presents original clinical reports and experimental studies by ophthalmologists and vision research scientists … Continued

Year Two results from the Comparison of Age-Related Macular Degeneration (AMD) Treatments Trials (CATT) that evaluated the effectiveness of Avastin (bevacizumab) versus Lucentis (ranibizumab) in a head-to-head clinical trial are now available. CATT is a multi-center, prospective clinical trial, funded by the National Eye Institute (NEI), a component agency of the National Institutes of Health. … Continued

Last week, I read yet another intriguing research study regarding the age-related macular degeneration (AMD) drugs Lucentis and Avastin. The newly-released Canadian study investigated the risk of cardiovascular events [i.e., heart attack, congestive heart failure, blood clotting, and stroke] in patients who were receiving either Avastin or Lucentis injections for retinal disease. I’ve blogged about … Continued

This week, I learned about a new clinical trial for a drug that shows promise in the treatment of wet macular degeneration (AMD) in patients who have not responded to treatment with either Avastin or Lucentis, the two drug interventions most commonly used at present. The drug is called iSONEP™ and it has been created … Continued